Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dermatophagoides pteronyssinus + lepidoglyphus destructor depigmented modified allergen extract
- Development stage
- Unknown
- Lead developer
- Leti Pharma
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Dermatophagoides pteronyssinus + Lepidoglyphus destructor depigmented modified allergen extract (DP/MG/14-1) is a subcutaneous allergen immunotherapy (SCIT) product developed by Laboratorios LETI S.L.U. It belongs to the Depigoid platform, which utilizes a proprietary process of depigmentation and polymerization (modification) of allergen extracts. This modification is intended to reduce the allergen's enzymatic activity and IgE-binding capacity (reducing the risk of systemic allergic reactions) while preserving its antigenicity and ability to induce immunological tolerance. The product contains extracts from two mite species: the house dust mite *Dermatophagoides pteronyssinus* and the storage mite *Lepidoglyphus destructor*. It is indicated for patients with allergic rhinitis, rhinoconjunctivitis, or controlled allergic asthma who demonstrate clinically relevant sensitization to these mites.
- Brand names
- Depigoid
- Other names
- Dermatophagoides pteronyssinus + Lepidoglyphus destructor depigmented modified allergen extractDP/MG/14-1depigmented modified house dust mite allergen mixture
02
Targets
TCR (T cell antigen receptor complex)BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on dermatophagoides pteronyssinus + lepidoglyphus destructor depigmented modified allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dermatophagoides pteronyssinus + lepidoglyphus destructor depigmented modified allergen extract.